US Stock MarketDetailed Quotes

IPHA Innate Pharma

Watchlist
  • 2.210
  • -0.050-2.21%
Close Aug 23 16:00 ET
178.90MMarket Cap-22100P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jun 17 00:03
    NEWS
    $Innate Pharma (IPHA.US)$
    Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
    Innate Pharma's Phase 1/2 trial of SAR443579 (SAR’579), developed with Sanofi, continues to show promising results for treating relapsed/refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high-risk myelodysplasia (HR-MDS). The clinical trial results, presented at the European Hematology Association 2024 Congress, hig...
    Jaguar8
    Jaguar8
    Jun 4 00:01
    NEWS
    $Innate Pharma (IPHA.US)$
    Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
    Innate Pharma has announced positive results from its Phase 2 TELLOMAK study, evaluating lacutamab in patients with mycosis fungoides (MF), a type of cutaneous T cell lymphoma. The study, presented at ASCO 2024, included 107 heavily pretreated patients. Lacutamab demonstrated significant anti-tumor activity, with an objective response rate (ORR) of 22.4% per Olse...
    Jaguar8
    Jaguar8
    May 24 00:10
    NEWS
    $Innate Pharma (IPHA.US)$
    Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
    Innate Pharma announced that five abstracts featuring its drug candidates have been accepted for presentation at the ASCO 2024 Annual Meeting, scheduled for May 31-June 4, 2024, in Chicago. Highlights include: - Topline results of the TELLOMAK Phase 2 trial for lacutamab in mycosis fungoides, confirming promising clinical activity. - Two posters on IPH6501, the second-generation ANKET® for CD20-...
    Jaguar8
    Jaguar8
    May 21 00:01
    $Innate Pharma (IPHA.US)$
    NEWS
    Innate Pharma: Clarification Regarding SAR443579 Designation
    Innate Pharma, listed on Euronext Paris (IPH) and Nasdaq (IPHA), clarified that their molecule SAR443579/IPH6101 was incorrectly mentioned as having breakthrough designation in an abstract published for the European Hematology Association 2024 Congress. The correct status is that the molecule has received US FDA Fast Track Designation, as communicated in June 2023. This clarification aims to rectify the mi...
    Jaguar8
    Jaguar8
    Apr 15 00:03
    $Innate Pharma (IPHA.US)$
    NEWS
    Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
    MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:
    Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monothe...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg